Guideline Perspectives and the Shift Toward Earlier ADC Integration

Here, Dr. Gradishar and the panel highlight the need to adapt to rapidly changing guidelines, especially with the advent of new combination therapies. Emphasis is placed on the enduring value of endocrine therapy with CDK4/6 inhibitors as a starting point, but also attention is paid to moving to triplet regimens with PI3K inhibitors in certain populations. The segment discusses strategies for transitioning to antibody-drug conjugates or chemotherapy when patients lose response to endocrine therapies. The nuanced approach to switching therapies as response durations shift demonstrates the complexity of managing advanced breast cancer today